Compare Coinbase Global, Inc. (COIN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Coinbase Global, Inc. trades at $149.1 (market cap $39.20B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| COIN | IDXX | |
|---|---|---|
Market Cap | $39.20B | $46.22B |
Sector | Technology | Health |
52-Week High | $387.27 | $766.68 |
52-Week Low | $141.09 | $526.44 |
Enterprise Value | $36.85B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $150.35, up 1.12% with bearish technical signals but strong analyst support (55% buy ratings). The company reported mixed Q2 2026 results with revenue and EPS misses, though it achieved a record 10.3% global trading volume share. Fundamentals show revenue growth from $3.1B in 2023 to $7.2B in 2025, but profitability remains volatile with recent quarterly losses.
The stock faces near-term pressure from earnings misses and crypto market volatility, but long-term potential exists through business diversification beyond retail trading. Key risks include competitive threats and regulatory uncertainty, while the $207.20 consensus price target suggests 38% upside if execution improves.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
